A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bristol-Myers Squibb
Related studies linked through entity extraction aliases.
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
- Status
- COMPLETED
- Phase
- PHASE2
An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants
- Status
- COMPLETED
- Phase
- PHASE1
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US
- Status
- COMPLETED
- Phase
- N/A
An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
- Status
- TERMINATED
- Phase
- PHASE3
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
- Status
- TERMINATED
- Phase
- PHASE2
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation
- Status
- COMPLETED
- Phase
- N/A
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes
- Status
- COMPLETED
- Phase
- PHASE1
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE1/PHASE2